Drug Interaction Report

ADJUST DOSING INTERVAL: Coadministration with beta-blockers may diminish the therapeutic effects of tasimelteon. Beta-blockers have been shown to reduce the production of melatonin via inhibition of beta-1 adrenergic receptors; therefore, the efficacy of tasimelteon, which acts as an agonist at melatonin MT1 and MT2 receptors, may be reduced.

MANAGEMENT: Product labeling for tasimelteon suggests avoiding the nighttime administration of beta-blockers.

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of tasimelteon. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

ADJUST DOSING INTERVAL: Food may delay the absorption and onset of action of tasimelteon. According to the product labeling, administration of tasimelteon with a high-fat meal decreased peak plasma concentration (Cmax) by 44% and delayed the median time to reach Cmax by approximately 1.75 hours compared to administration in the fasted state.

MONITOR: Smoking induces CYP450 1A2 and may reduce the plasma concentrations of tasimelteon, which is metabolized by the isoenzyme. According to the product labeling, tasimelteon systemic exposure was approximately 40% lower in smokers than in nonsmokers.

MANAGEMENT: Patients receiving tasimelteon should be advised to avoid or limit consumption of alcohol. Tasimelteon should be taken without food. Patients who smoke may have a reduced therapeutic response to tasimelteon.